BIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING

SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (NASDAQ: BNGO), a genome analysis company that provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, today announced the pricing of an underwritten public offering of 54,546,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and common warrants to purchase up to an aggregate of 54,546,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.33 per share and accompanying common warrant. For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis.

The common warrants will be immediately exercisable at a price of $0.33 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about April 6, 2020, subject to customary closing conditions. 

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. Roth Capital Partners is acting as the lead manager, and Maxim Group LLC is acting as the as co-lead manager.

The gross proceeds to Bionano from this offering are expected to be approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bionano, and excluding any proceeds that may be received upon exercise of the common warrants. Bionano anticipates using the net proceeds from the offering for general corporate purposes, including working capital, sales and marketing activities, general and administrative matters and capital expenditures.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on April 1, 2020. The offering is being made only by means of a prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting the SEC’s website at http://www.sec.gov, or alternatively from the offices of Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26^th Floor, New York, New York 10004, by telephone at 212-667-8055, or by email at [e-mail].